FAS has upgraded our forum security. Some members may need to log in again. If you are unable to remember your login information, please email food.allergy.supt@flash.net and we will help you get back in. Thanks for your patience!

« previous next »
Pages: [1]   Go Down

Author Topic: Current barriers to adrenaline auto-injector use  (Read 1502 times)

Description:

Offline LinksEtc

  • Member
  • ***
  • Posts: 2,746
Current barriers to adrenaline auto-injector use
« on: July 03, 2014, 05:30:58 PM »
Tweeted by @Allergy

"Anaphylaxis treatment: current barriers to adrenaline auto-injector use"
http://onlinelibrary.wiley.com/doi/10.1111/all.12387/full?utm_content=bufferb6b2b&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

Quote
The aim of this review is to highlight the barriers that exist to the use and availability of AAIs and that prevent proper management of anaphylaxis. In addition, we review the characteristics of all AAIs that are presently available in Europe and the USA and discuss the need for regulatory requirements to establish the performance characteristics of these devices.
Logged

Offline LinksEtc

  • Member
  • ***
  • Posts: 2,746
Re: Current barriers to adrenaline auto-injector use
« Reply #1 on: July 09, 2014, 02:24:53 PM »
Tweeted by @AllergieVoeding

"Status of children with food allergy who were prescribed an adrenaline autoinjector (epipen)"
http://www.ncbi.nlm.nih.gov/pubmed/24865961?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter

Quote
CONCLUSION:
These results suggest that the autoinjector is often not used appropriately after prescription. Therefore, children and their caregivers require more effective guidance on proper adrenaline autoinjector use.
Logged
Pages: [1]   Go Up
« previous next »
 

+ Quick Reply